## **Supplementary Material**

## **Supplementary Methods**

**Supplementary Table S1.** Clinicopathological characteristics of patients in the current study cohort.

Supplementary Table S2. Primary tumor mutations detected through sequence analysis of Set 2 samples using Ion Proton<sup>TM</sup> and circulating tumor DNA levels (ctDNA) measured by digital PCR.

**Supplementary Table S3.** Primary tumor mutations detected through sequence analysis of Set 3 samples using Ion 5S<sup>™</sup> and circulating tumor DNA (ctDNA) levels measured by digital PCR.

**Supplementary Figure S1.** Somatic mutation profile of primary CRC tumors from the 52 patients in the current study cohort.

**Supplementary Figure S2.** Dynamics of ctDNA in 42 patients with CRC without clinical relapse.

**Supplementary Figure S3.** Longitudinal CEA monitoring of patients with CRC during the postoperative period.

**Supplementary Figure S4.** Comparison of relapse free survival (RFS) rates according to relapse type.

## **Supplementary Methods**

### Identifying somatic mutations in primary tumor tissue

Sequencing analysis of the primary tumor was performed using three different platforms for three sets of patients with colorectal cancer (CRC). Tumor samples from 11, 27, and 14 patients were analyzed for Sets 1, 2, and 3, respectively. Set 1 was analyzed using an Illumina Hiseq 2000 sequencer (Illumina, Inc., San Diego, CA) with the ClearSeq Comprehensive Cancer Panel (Agilent Technologies, Inc., Santa Clara, CA) that targets 151 disease-associated genes (Ref. 35 of the main text). Sets 2 and 3 were analyzed using the Ion Proton<sup>™</sup> and Ion S5<sup>™</sup> system (Thermo Fisher Scientific, Waltham, MA), respectively, with a customized panel targeting 39 genes that are frequently altered in CRC.<sup>1</sup> Set 1 samples were analyzed in our previous study, which considered three regions of the primary tumor and corresponding DNA from peripheral blood mononuclear cells (PBMCs) (total of four samples) to assess the effect of intra-tumor genetic heterogeneity on circulating tumor DNA (ctDNA) (Ref. 35 of the main text). In that study, the results indicated that tumor genetic heterogeneity did not present a major obstacle for ctDNA analysis provided that a somatic mutation having a sufficient variant allele frequency (VAF) was selected from a single region of the tumor. Furthermore, commonly detected mutations among the three tumor regions were limited to a set of genes that included TP53, APC, KRAS, PIK3CA, FBXW7, and BRAF.

For Set 2, the pairing between DNAs from tumor andPBMC, was analyzed using an Ion Proton<sup>TM</sup> system (Thermo Fisher Scientific, Waltham, MA) with a customized panel targeting 39 genes specific for CRC. This approach was designed to reduce costs and improve the efficiency of mutation detection by tumor sequencing. Amplicon sequencing followed by identification of somatic mutations using the tumor-normal workflow of Ion Reporter software 5.0 (Thermo Fisher Scientific) was performed as previously described (Refs. 34 and 37 of the main text). The following criteria were used as cutoffs: (1) total coverage >200, (2) variant coverage >10, and (3) variant frequency >10%. Mutations were called if they occurred in <0.1% of the reads in the normal control (minor allele frequency) and were absent from the dbSNP and 1000 Genomes Project database.

For Set 3, we analyzed only tumor DNA samples from a single region using an Ion  $S5^{TM}$  system (Thermo Fisher Scientific). This approach considered the high mutation detection efficiency of tumor sequencing using the customized panel for Set 2. Alignment to reference genomes and sequencing read counting were performed with Torrent Suite version 5.0 (Thermo Fisher Scientific), Hisat2 (https://ccb.jhu.edu/software/hisat2/index.shtml), and BWA (Burrows–Wheeler

Alignment tool). For such cases, commonly-detected mutations among the three algorithms were prioritized in subsequent mutation selection. The following criteria were used as cutoffs: (1) total coverage >200, (2) variant coverage >10, and (3) variant frequency >10%. Mutations were selected as described for Set 2. Furthermore, mutations were called if they also occurred with minor allele frequencies (MAF <0.01) in the Japanese SNP database of the Tohoku Medical Megabank Organization (ToMMo).<sup>2</sup> Moreover, the same mutations shared among more than 3 of the 14 patients in Set 3 were excluded from selection since the mutations did not frequently occur in CRC and thus the likelihood that they resulted from sequencing errors was high. For insertion and deletion mutations, the following criteria were used as cutoffs: (1) total coverage >200; (2) variant coverage >10; and (3) variant frequency >20%. For Set 3, the dPCR probe/premier set for each specific mutation was designed after confirming that Sanger sequencing detected the mutation in tumor DNA but not in PBMC DNA.

Clonal hematopoiesis of indeterminate potential variants was removed by paired PBMC sequencing for Sets 1 and 2, and for Set 3 by confirming the absence of the corresponding specific mutation in PBMC DNA by Sanger sequencing.

### Criteria for mutation selection in ctDNA assays using digital PCR

Specific primers and probes labeled for wild-type and mutant alleles were specifically designed for each mutation identified in a primary tumor using Hypercool Primer & Probe<sup>™</sup> technology (Nihon Gene Research Laboratories, Sendai, Japan). For frequently recurring missense mutations, commercially available primer/probe sets were used (Quantdetect, Inc., Tokyo, Japan; Thermo Fisher Scientific, Waltham, MA). According to our previous studies, between 1 and 5 mutations having VAFs >10% that were found in primary tumors were prioritized for digital PCR (dPCR) analysis (References 34-37 of the main text). The criteria used to select mutations for ctDNA assay were: (1) the mutation having the highest VAF in the primary tumor; (2) up to four additional mutations having a VAF >10% in the primary tumors; (3) recurrent mutations observed among patients; (4) mutated genes having a high success rate for primer/probe validation; and (5) exclusion of mutations with a surrounding sequence that was suspected of having low PCR efficiency and low specificity of hybridized probes (e.g., selfcomplementarity and/or secondary structure of the primer/probe). Furthermore, those mutations that were already validated in tumor DNA from CRC or other types of malignancies could reduce the temporary cost and time needed for syntheses of specifically-designed probes for each tumor-specific mutation. Therefore, mutations listed in our dPCR primer/probe library and commercially available primer/probe sets

(Quantdetect, Inc, Tokyo, Japan) were analyzed, even if the mutations detected in the primary tumors did not satisfy the criteria for mutation selection.

## Definitions of ctDNA positivity and negativity in dPCR assays

As previously described (References 34-37 of the main text), dPCR was performed using the QuantStudio3D Digital PCR system (Thermo Fisher Scientific). After PCR amplification, chips were read on a QuantStudio 3D Digital PCR Instrument (Thermo Fisher Scientific), and a secondary analysis was performed using QuantStudio 3D Analysis Suit Cloud software (Thermo Fisher Scientific). For further quality control, the boundaries of FAM, VIC, and undetermined events were manually defined. After confirmation of sufficiently separate reactions of both wild-type and mutant alleles in tumor DNA, plasma DNA was evaluated by dPCR. Plasma samples having more than two positive reactions (i.e., dots) for mutant DNA were defined as ctDNA-positive. If only one positive reaction for mutant DNA was detected, samples were considered to be ctDNA-positive when more than one positive reaction for mutant DNA could be repeatedly detected upon retesting of the same sample. The VAF values were calculated as the fraction of mutant/(mutant + wild) divided by the number of partitions in which either the mutant or wild-type sequence was detected.<sup>3</sup> If no mutant partitions were detected, the case DNA was regarded as "negative".

## References

- Nakanishi H, Sawada T, Kaizaki Y, et al. Significance of gene mutations in the Wnt signaling pathway in traditional serrated adenomas of the colon and rectum. PLoS One 2020;15:e0229262.
- 2. Okuda H, Okamoto K, Abe M, et al. Correction to: Genome-wide association study identifies new loci for albuminuria in the Japanese population. Clin Exp Nephrol 2021;25:565.
- Huggett JF, Foy CA, Benes V, et al. The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments. Clin Chem 2013;59:892-902.

## Supplementary Table S1. Clinicopathological characteristics of patients in the current study cohort.

Detient No.	Age	Carr	Sex Primary tumor Size UICC stage <sup>a</sup>			а	Preoperative			
Patient No.	range	Sex	location	(mm²)	Т	depth	Ν	М	pStage <sup>b</sup>	organ
CC16001	71-75	Female	Cecum	47×60	4a	SE	1a	0	IIIB	-
CC16002	81-85	Female	Cecum	57×35	3	SS	0	0	Ш	-
CC16003	51-55	Female	Rectum	23×22	3	SS	2	0	IIIB	-
CC16005	71-75	Female	Rectosigmoid	22×20	2	MP	1b	0	IIIA	-
CC16006	51-55	Male	Sigmoid	9×11	1b	SM	0	0	I	-
CC16008	71-75	Female	Cecum	26×20	2	MP	1b	0	IIIA	-
CC16009	86-90	Female	Rectum	60×75	4a	SE	0	0	Ш	-
CC16010	56-60	Female	Rectum	35×70	4a	AI	2b	1a	IVB	Liver
CC16011	51-50	Female	Sigmoid	37×48	4a	SE	1a	1a	IVA	LN °
CC16012	56-60	Female	Sigmoid	53×49	3	SS	0	0	Ш	-
CC16013	76-80	Female	Rectum	65×50	3	SS	0	0	Ш	-
CC16014	51-55	Female	Rectum	85×57	3	SS	0	0	Ш	-
CC16015	71-75	Male	Sigmoid	9×11	4b	SM	0	0	IIC	-
CC16016	51-55	Male	Sigmoid	28×28	3	SS	1a	0	IIIB	-
CC16017	76-80	Female	Ascending	103×72	3	SS	1b	0	IIIA	-
CC16018	81-85	Male	Ascending	42×30	3	SS	х	0	IIA	-
CC16019	71-75	Male	Transverse	110×103	4a	SE	0	0	IIB	-
CC16020	71-75	Female	Sigmoid	35×70	3	SS	1a	0	IIIB	-
CC16021	71-75	Male	Ascending	39×42	3	SS	0	0	IIA	-
CC16022	56-60	Male	Rectum	50×42	2	MP	0	0	I	-
CC16023	81-85	Female	Cecum	55×82	3	SS	2b	0	IIIC	-
CC16024	36-40	Female	Rectum	61×45	3	SS	0	0	IIA	-
CC16025	71-75	Male	Ascending	37×26	3	SS	0	0	IIA	-
CC16026	76-80	Female	Ascending	58×49	3	SS	0	0	IIA	-
CC16027	76-80	Female	Ascending	34×29	3	SS	1	0	IIIA	-
CC16028	51-55	Female	Sigmoid	20×17	2	MP	0	0	I	-
CC16029	56-60	Female	Sigmoid	46×42	3	SS	1a	0	IIIB	-
CC16030	66-70	Male	Ascending	17×20	3	SS	1b	0	IIIB	-
CC16031	76-80	Male	Sigmoid	33×30	1	CIS	0	0	I	-

CC16032	71-75	Female	Ascending	73×63	4a	SE	1b	0	IIIB	-	
CC16034	76-80	Female	Sigmoid	43×60	3	SS	1a	0	IIIB	-	
CC16035	61-65	Male	Rectum	21×17	3	SS	2a	0	IIIB	-	
CC16036	81-85	Female	Cecum	27×26	2	1b	0	0	IIIA	-	
CC16037	51-55	Female	Sigmoid	58×32	3	SS	0	0	IIA	-	
CC16038	61-65	Male	Ascending	32×26	3	SS	0	0	IIA	-	
CC16039	81-85	Male	Transverse	27×26	3	SS	0	0	IIA	-	
CC16040	71-75	Female	Sigmoid	25×22	3	SS	0	0	IIA	-	
CC16041	66-70	Male	Rectum	35×42	3	SS	2a	0	IIIB	-	
CC16042	66-70	Female	Sigmoid	54×33	3	SS	2a	0	IIIB	-	
CC16043	56-60	Female	Transverse	47×28	3	SS	2a	0	IIIB	-	
CC16044	71-75	Male	Rectum	52×35	3	SS	0	0	IIA	-	
CC16046	76-80	Male	Sigmoid	40×37	3	SS	0	0	IIA	-	
CC16047	66-70	Female	Rectum	57×32	3	SS	0	0	IIA	-	
CC16048	66-70	Female	Sigmoid	58×32	3	SS	0	0	IIA	-	
CC16049	81-85	Female	Sigmoid	53×52	3	SS	0	0	IIA	-	
CC16050	66-70	Female	Transverse	47×30	3	SS	0	0	IIA	-	
CC16051	66-70	Female	Rectum	88×62	3	SS	0	0	IIA	-	
CC16054	66-70	Male	Ascending	35×55	3	SS	1a	0	IIIB	-	
CC16056	56-60	Male	Rectum	43×60	4b	SE	2b	0	IIIC	-	
CC16057	61-65	Male	Transverse	35×52	4b	SE	2a	0	IIIC	-	
CC16058	66-70	Male	Rectum	63×48	3	SS	0	0	IIA	-	
CC16060	61-65	Male	Rectum	80×100	3	SS	0	0	IIA	-	

<sup>a</sup> TNM classification, 8th edition

<sup>b</sup> Pathological stage

° Nonregional abdominal para-aortic lymph nodes

# Supplementary Table S2. Primary tumor mutations detected through sequence analysis of Set 2 samples using lon Proton<sup>™</sup> and circulating tumor DNA levels (ctDNA) measured by digital PCR.

Case ID	Chromosomal location	Gene	Variant type	Base change	Amino acid change	Total allele	Wild type	Mutant allele	Primary VAF <sup>a</sup> (%)	dPCR⁵	pre ctDNA <sup>c</sup> (%)
CC16002	chr12:25398280	KRAS	missense	c.37G>T	p.G13C	1995	1790	205	10.3	yes	0
	chrX:63411678	AMER1	nonsense	c.1489C>T	p.R497*	1997	1385	612	30.6		
CC16003	chr5:112175639	APC	nonsense	c.4348C>T	p.R1450*	1999	1021	978	48.9		
	chr17:7578256	TP53	nonsense	c.586C>T	p.R196*	1948	1025	923	47.4	yes	0.43
	chr14:21868397	CHD8	missense	c.4640A>G	p.H1547R	1998	1586	412	20.62		
CC16006	chr12:25398283	KRAS	missense	c.34G>T	p.G12C	1998	1779	218	10.91	yes	0
	chr17:7578368	TP53	splicesite_3	c.559+3G>C		1920	1543	376	19.6		
	chr17:63554007	AXIN2	frameshift deletion	c.731delC	p.S244fs	1991	1228	763	38.3		
0010000	chr12:25398283	KRAS	missense	c.35G>A	p.G12D	1997	1459	538	26.9	yes	0.25
CC 16009	chr2:48027519	MSH6	missense	c.2397G>A	p.M799I	2000	1677	323	16.2		
	chr17:7578368	TP53	splicesite_3	c.559+3G>C		1910	1274	635	33.2		
	chr5:112175639	APC	nonsense	c.4348C>T	p.R1450*	1996	1081	915	45.8		
0016017	chr5:112173914	APC	nonsense	c.2623A>T	p.K875*	1999	1167	832	41.6		
0010017	chr3:41278106	CTNNB1	missense	c.1982G>T	p.R661L	1998	1101	897	44.9		
	chr12:25378561	KRAS	missense	c.437C>T	p.A146V	1550	869	681	43.9		

	chr1:115258745	NRAS	missense	c.37G>C	p.G13R	2000	1492	506	25.3		
	chr3:178936082	PIK3CA	missense	c.1624G>A	p.E542K	1318	1017	301	22.8	yes	0
	chr5:112175672	APC	frameshift deletion	c.4391_4394delAGAG	p.E1464fs	1949	1525	423	21.70		
CC16018	chr5:112174631	APC	nonsense	c.3340C>T	p.R1114*	1999	1589	410	20.51		
	chr17:7577546	TP53	missense	c.733G>A	p.G245S	1993	1421	570	28.60	yes	0.18
0010010	chr7:140453133	BRAF	missense	c.1799T>A	p.V600E	1980	1632	347	17.53	yes	11.9
CC16019	chr17:7577120	TP53	missense	c.818G>A	p.R273H	1966	1165	801	40.74	yes	4.57
0010000	chr5:112151261	APC	missense	c.904C>T	p.R302*	1998	1107	891	44.59	yes	0.17
CC 16020	chr17:7578474	TP53	missense	c.451C>G	p.P151A	1616	809	803	49.69	yes	0.75
	chr7:140453155	BRAF	missense	c.1780G>C	p.D594H	1991	1507	484	24.31	yes	0
CC16021	chr20:57485014	GNAS	missense	c.848G>A	p.R283H	1998	1556	442	22.12		
	chr12:25378562	KRAS	missense	c.436G>A	p.A146T	1999	1762	237	11.86		
	chr5:112128203	APC	nonsense	c.706C>T	p.Q236*	1999	1612	387	19.36		
	chr4:153247376	FBXW7	nonframeshift deletion	c.1423_1425delGTT	p.V475del	1984	1114	870	43.85		
CC16022	chr4:153332760	FBXW7	frameshift insertion	c.195_196insGA	p.P66fs	1997	1522	475	23.79		
	chr12:25398280	KRAS	missense	c.38G>A	p.G13D	1997	1050	944	47.27	yes	0.55
	chr17:7578474	TP53	missense	c.451C>A	p.P151T	1978	782	1194	60.36		
CC16024	chr2:148683611	ACVR2A	nonsense	c.1228G>T	p.E410*	1893	1278	615	32.49		

0

chr5:112175046	APC	missense	c.3755C>A	p.S1252Y	1914	862	653	34.12	
chr1:27106178	ARID1A	nonsense	c.5789C>A	p.S1930*	1092	807	285	26.10	
chr11:108202715	ATM	missense	c.7739G>T	p.R2580I	1997	1418	579	28.99	
chr11:108196939	ATM	missense	c.6962C>T	p.A2321V	1998	1471	527	26.38	
chr14:21871721	CHD8	missense	c.3409C>A	p.L1137I	1999	1461	538	26.91	
chr14:21860965	CHD8	missense	c.6472C>T	p.R2158C	1993	1491	502	25.19	
chr3:41277291	CTNNB1	missense	c.1760G>A	p.R587Q	1998	1352	646	32.33	
chr3:41266232	CTNNB1	nonsense	c.229G>T	p.E77*	1994	1441	553	27.73	
chr8:42231798	DKK4	missense	c.495T>G	p.I165M	1431	1172	259	18.10	
chr4:153244184	FBXW7	missense	c.1973G>A	p.R658Q	1977	1405	572	28.93	
chr4:153332915	FBXW7	missense	c.41G>A	p.R14Q	1979	1463	516	26.07	
chr12:130648241	FZD10	missense	c.754G>A	p.D252N	1991	1407	584	29.33	
chr12:130648713	FZD10	missense	c.1226G>A	p.G409D	1999	1457	542	27.11	
chr12:130647576	FZD10	missense	c.89G>A	p.G30D	1844	1509	335	18.17	
chr3:119624687	GSK3B	missense	c.728C>T	p.A243V	694	507	187	26.95	
chr2:48027661	MSH6	nonsense	c.2539G>T	p.E847*	203	129	74	36.45	yes
chr3:178916716	PIK3CA	nonsense	c.103G>T	p.E35*	1391	972	419	30.12	
chr3:178922301	PIK3CA	missense	c.1070G>A	p.R357Q	2000	1446	554	27.70	
chr3:178916642	PIK3CA	missense	c.29T>G	p.L10R	2000	1593	407	20.35	

	chr10:89692895	PTEN	missense	c.389G>A	p.R130Q	1972	1462	510	25.86		
	chr17:56435626	RNF43	missense	c.1511A>G	p.D504G	1999	1729	270	13.51		
	chr18:48603033	SMAD4	missense	c.1334G>A	p.R445Q	1402	1023	379	27.03		
	chr17:6676434	XAF1	missense	c.852G>T	p.E284D	365	304	61	16.71		
CC16025	chrX:63410048	AMER1	missense	c.3119C>A	p.A1040D	2000	1773	227	11.35	yes	0
	chr20:57484420	GNAS	missense	c.601C>T	p.R201C	1999	1441	558	27.91		
	chr12:25378562	KRAS	missense	c.436G>A	p.A146T	1999	590	1409	70.49		
CC16028	chr3:178936091	PIK3CA	missense	c.1633G>A	p.E545K	1999	1161	838	41.92	yes	0
	chr10:114912175	TCF7L2	frameshift deletion	c.1247delG	p.G416fs	1991	946	1045	52.49		
	chr17:7578443	TP53	missense	c.476C>T	p.A159V	1932	596	1336	69.15		
	chr5:112173917	APC	nonsense	c.2626C>T	p.R876*	2000	1535	465	23.25	yes	0
0010000	chr5:112175628	APC	frameshift deletion	c.4338delT	p.Q1447fs	1987	1533	454	22.85		
CC 16029	chr4:153258983	FBXW7	nonsense	c.832C>T	p.R278*	1653	1285	368	22.26		
	chr17:7578490	TP53	nonsense	c.438G>A	p.W146*	1824	1203	621	34.05		
	chrX:63411969	AMER1	nonsense	c.1198G>T	p.E400*	1568	484	1084	69.13		
	chr5:112176020	APC	nonsense	c.4729G>T	p.E1577*	959	633	326	33.99		
CC16030	chr5:112173736	APC	frameshift Insertion	c.2454_2455insTGGCAAC	p.M819fs	1996	1641	355	17.79		
	chr12:25378561	KRAS	missense	c.437C>T	p.A146V	1993	728	1265	63.47	yes	0.51
	chr10:89720665	PTEN	nonsense	c.821G>A	p.W274*	212	122	90	42.45		

	chr17:7577021	TP53	nonsense	c.916C>T	p.R306*	2000	1100	900	45.00	yes	0
CC16031	chr17:70117936	SOX9	missense	c.404T>A	p.L135H	1997	1762	235	11.77	yes	0.06
	chrX:63412020	AMER1	nonsense	c.1147G>T	p.E383*	1999	1385	614	30.72		
	chr5:112174682	APC	nonsense	c.3391C>T	p.Q1131*	1998	1629	369	18.47		
0040000	chr12:25398280	KRAS	missense	c.38G>A	p.G13D	1996	1534	462	23.15	yes	0.22
CC 16036	chr11:68179025	LRP5	missense	c.2440G>A	p.A814T	1994	1754	240	12.04		
	chr3:178936094	PIK3CA	missense	c.1636C>A	p.Q546K	545	408	137	25.14		
	chr17:7577156	TP53	splicesite_5	c.783-1G>A		1972	1348	624	31.64		
0016027	chr5:112170648	APC	nonsense	c.1744G>T	p.E582*	2000	1680	320	16.00		
0010037	chr17:7577556	TP53	missense	c.722C>G	p.S241C	1978	1187	788	39.84	yes	0.27
CC16038	chr12:25398280	KRAS	missense	c.38G>A	p.G13D	1998	1822	176	8.81	yes	0
CC16030	chr15:65116026	PIF1	missense	c.509C>T	p.T170M	813	656	157	19.31		
0010039	chr17:7577553	TP53	frameshift Insertion	c.714_715insGT	p.N239fs	1492	666	825	55.29	yes	0
	chr5:112173917	APC	nonsense	c.2626C>T	p.R876*	1997	857	1140	57.09	yes	0
	chr1:27107138	ARID1A	frameshift deletion	c.6750delG	p.E2250fs	1998	1231	767	38.39		
CC16040	chr12:25398283	KRAS	missense	c.35G>A	p.G12D	1999	1255	744	37.22	yes	13.2
	chr3:178936095	PIK3CA	missense	c.1637A>G	p.Q546R	697	273	424	60.83		
	chr17:7578256	TP53	missense	c.584T>C	p.I195T	1949	797	1152	59.11		

CC16044	chr5:112116592	APC	nonsense	c.637C>T	p.R213*	1687	727	960	56.91	yes	1.73
CC16044	chr4:153249511	FBXW7	missense	c.1267G>A	p.G423R	1998	1280	718	35.94		
	chr5:112173718	APC	frameshift deletion	c.2428delA	p.R810fs	1995	1195	800	40.10		
0040040	chr5:112128141	APC	splicesite_5	c.646-2A>G		1065	668	397	37.28		
CC16046	chr12:25398283	KRAS	missense	c.35G>A	p.G12D	1997	1209	784	39.26	yes	0
	chr3:178952085	PIK3CA	missense	c.3140A>G	p.H1047R	1999	1210	788	39.42	yes	0.84
	chr5:112128143	APC	nonsense	c.646C>T	p.R216*	1083	393	690	63.71		
CC16047	chr15:65112165	PIF1	missense	c.1214G>A	p.R405H	1905	1357	548	28.77		
	chr3:178936091	PIK3CA	missense	c.1633G>A	p.E545K	671	452	219	32.64	yes	0
	chr7:140453133	BRAF	missense	c.1799T>A	p.V600E	1979	881	1096	55.38	yes	0
CC16048	chr4:153258983	FBXW7	nonsense	c.832C>T	p.R278*	1999	1243	756	37.82		
CC10048	chr12:130648458	FZD10	missense	c.971C>T	p.S324L	2000	1229	771	38.55		
	chr17:7579348	TP53	frameshift deletion	c.338delT	p.F113fs	1992	1266	724	36.35		
CC16040	chr12:25398283	KRAS	missense	c.35G>T	p.G12V	2000	1250	747	37.35	yes	0
CC 16049	chr17:7577528	TP53	missense	c.742C>T	p.R248W	1963	576	1386	70.61		
	chr5:112174580	APC	nonsense	c.3289G>T	p.E1097*	1997	1214	783	39.21		
CC16050	chr14:21876575	CHD8	nonsense	c.2626C>T	p.R876*	1997	882	1115	55.83		
	chr4:153247367	FBXW7	nonsense	c.1435C>T	p.R479*	1765	1210	555	31.44		

chr17:70117938	SOX9	missense	c.406A>G	p.S136G	2000	738	1262	63.10		
chr17:7577580	TP53	missense	c.701A>G	p.Y234C	1980	534	1446	73.03	yes	0

<sup>a</sup> Variant allele frequency

<sup>b</sup> Plasma DNA was evaluated by dPCR

° Pretreatment circulating tumor DNA

# Supplementary Table S3. Primary tumor mutations detected through sequence analysis of Set 3 samples using lon 5S<sup>™</sup> and circulating tumor DNA (ctDNA) levels measured by digital PCR.

Case ID	Chromosomal location	Gene	Variant type	Base change	Amino acid change	Total allele	Wild type	Mutant allele	Primary VAFª (%)	dPCR⁵	pre ctDNA <sup>c</sup> (%)
CC16010	chr17:7675108	TP53	frameshift insertion	c.107_108insAGCA	p.H36Qfs*14	4610	2983	981	21.11	yes	8.54
	chr5:112839729	APC	stopgain	c.G4135T	p.E1379*	3959	2075	1880	47.49		
0040040	chr12:25245350	KRAS	nonsynonymous	c.G35T	p.G12V	7680	3872	3802	49.51	yes	0.51
CC 16012	chr20:37035354	RBL1	frameshift insertion	c.776dupC	p.S260Ffs*6	4520	3858	1198	23.58		
	chr17:7675232	TP53	nonsynonymous	c.C380A	p.S127Y	3021	605	2384	78.91	yes	0.19
	chr11:108335029	ATM	nonsynonymous	c.C8071T	p.R2691C	3427	2342	983	29.53		
	chr7:140753336	BRAF	nonsynonymous	c.T1799A	p.V600E	5149	3438	1697	32.95	yes	0
	chr20:58855061	GNAS	nonsynonymous	c.G1796A	p.R599H	4196	2611	1576	37.55		
CC 160 13	chr3:179234297	PIK3CA	nonsynonymous	c.A3140G	p.H1047R	5276	3295	1969	37.26	yes	0
	chr17:58362564	RNF43	nonsynonymous	c.C667T	p.R223C	2587	1341	1245	48.13		
	chr10:113165642	TCF7L2	frameshift deletion	c.1411delC	p.S473Pfs*5	2148	1442	671	30.74		
	chr5:112839693	APC	frameshift insertion	c.4046dupA	p.T1350Dfs*7	2540	1707	837	32.66	yes	8.3
CC16014	chr14:21393628	CHD8	nonsynonymous	c.G6167A	p.R2056Q	2700	1565	1112	41.12		
	chr17:7675131	TP53	nonsynonymous	c.G481A	p.A161T	2370	1545	814	34.39	yes	8.68
CC16015	chr11:108229288	ATM	nonsynonymous	c.G296A	p.S99N	2630	2047	558	21.17		

	chr11:108229289	ATM	nonsynonymous	c.T297G	p.S99R	2543	1999	543	21.36		
	chr7:140800366	BRAF	nonsynonymous	c.A976G	p.1326V	6118	2861	3254	53.17		
	chr3:37025979	MLH1	stopgain	c.A658T	p.K220*	2536	1912	620	24.45		
	chr17:58358121	RNF43	nonsynonymous	c.G1274A	p.R425H	7705	5986	1689	21.95		
	chr17:58358788	RNF43	stopgain	c.C988T	p.R330*	1226	249	32	11.27	yes	2.43
	chr17:58363351	RNF43	nonsynonymous	c.C125A	p.A42D	2536	1912	620	24.45		
CC16026	chr5:112775687	APC	stopgain	c.C481T	p.Q161*	2430	1392	1027	42.21		
0010020	chr12:25245350	KRAS	nonsynonymous	c.G35A	p.G12D	7144	5172	1967	27.54	yes	0
	chr5:112839942	APC	stopgain	c.C4348T	p.R1450*	3185	2036	1148	36.02		
CC16027	chr12:25245350	KRAS	nonsynonymous	c.G35T	p.G12V	5261	3070	2188	41.6	yes	0
	chr17:7675180	TP53	frameshift insertion	c.35_36insTGCA	p.Q12Hfs*6	2962	1151	1804	60.42	yes	0.27
	chr5:112839879	APC	stopgain	c.C4285T	p.Q1429*	2611	1315	1265	48.37		
	chr1:26772550	ARID1A	frameshift deletion	c.3458delC	p.M1154Wfs*7	2596	1311	1291	49.43		
	chr17:65537787	AXIN2	nonsynonymous	c.G1249T	p.A417S	2424	1763	518	22.7		
CC16032	chr1:114713909	NRAS	nonsynonymous	c.C181A	p.Q61K	3255	2100	1053	33.31	yes	21.6
0010032	chr3:179218303	PIK3CA	nonsynonymous	c.G1633A	p.E545K	1015	766	249	24.53	yes	11.8
	chr18:51078425	SMAD4	frameshift deletion	c.1618delC	p.L540Ffs*12	2693	1435	1279	47.02		
	chr17:72121597	SOX9	frameshift deletion	c.207delC	p.V71Cfs*39	2040	1510	462	22.42		
	chr17:7673763	TP53	frameshift deletion	c.460delG	p.E154Kfs*59	1751	856	899	51.17	yes	0.19

CC16051	chr5:112839117	APC	stopgain	c.C3523T	p.Q1175*	4098	3380	707	17.21		
CC 10051	chr17:7675088	TP53	nonsynonymous	c.G524A	p.R175H	7057	6177	872	12.34	yes	0.31
	chrX:64192215	AMER1	stopgain	c.C1072T	p.R358*	3751	770	2980	79.42		
	chrX:64191813	AMER1	frameshift insertion	c.1473dupC	p.R492Qfs*16	1573	1447	372	20.26		
	chrX:64191986	AMER1	frameshift insertion	c.1300dupC	p.H434Pfs*7	499	265	268	49.91		
	chrX:64192785	AMER1	frameshift insertion	c.501dupA	p.G168Rfs*7	287	141	193	57.78		
	chrX:64193123	AMER1	frameshift insertion	c.163dupA	p.T55Nfs*17	2999	2365	707	22.91		
	chr5:112838455	APC	stopgain	c.T2861A	p.L954*	4502	2996	1494	33.11		
	chr5:112840155	APC	stopgain	c.G4561T	p.E1521*	3346	2651	682	20.36		
	chr5:112840372	APC	nonsynonymous	c.A4724G	p.K1575R	645	566	77	11.94		
CC16054	chr5:112841875	APC	nonsynonymous	c.C6281T	p.P2094L	4071	3606	461	11.32		
	chr5:112819329	APC	frameshift insertion	c.1244dupA	p.D416Gfs*10	941	711	296	29.37		
	chr5:112840383	APC	frameshift insertion	c.4736dupC	p.A1580Cfs*34	588	484	191	28.25		
	chr1:26773683	ARID1A	nonsynonymous	c.T3970C	p.Y1324H	1768	1573	187	10.56		
	chr1:26773685	ARID1A	stopgain	c.C3972A	p.Y1324*	1482	1238	204	14.14		
	chr1:26779587	ARID1A	nonsynonymous	c.C5689G	p.P1897A	1764	903	370	28.95		
	chr1:26774569	ARID1A	frameshift insertion	c.4343dupC	p.G1449Rfs*42	546	297	297	49.25		
	chr1:26774597	ARID1A	frameshift insertion	c.4371dupC	p.Q1458Pfs*33	634	390	267	40.39		
	chr1:26774620	ARID1A	frameshift insertion	c.4394dupC	p.A1466Cfs*25	830	643	236	26.85		

chr11:108244102	ATM	frameshift insertion	c.646_647insT	p.A216Vfs*38	1826	1183	626	33.23		
chr11:108281146	ATM	frameshift insertion	c.3555dupA	p.E1186Rfs*14	850	547	349	38.86		
chr8:60852937	CHD7	frameshift deletion	c.6213delC	p.Q2073Sfs*71	1740	1153	561	31.22		
chr8:60865588	CHD7	frameshift insertion	c.2503dupC	p.S836Lfs*56	1880	801	1108	57.29		
chr14:21391024	CHD8	stopgain	c.A7105T	p.K2369X	1101	937	150	13.57		
chr20:58853838	GNAS	nonsynonymous	c.T386C	p.L129P	2997	1550	1441	48.03		
chr12:25245350	KRAS	nonsynonymous	c.G35A	p.G12D	7392	3692	3700	50.05	yes	0
chr12:25225691	KRAS	frameshift insertion	c.372dupA	p.V125Sfs*19	837	601	337	35.93		
chr11:68390006	LRP5	frameshift insertion	c.1539dupG	p.E514Gfs*20	818	603	244	28.74		
chr11:68403698	LRP5	frameshift insertion	c.1801dupG	p.T602Nfs*35	317	235	88	27.16		
chr11:68425992	LRP5	frameshift insertion	c.1699_1700insG	p.T567Sfs*73	1545	953	714	41.34		
chr3:37025946	MLH1	nonsynonymous	c.G625A	p.D209N	2946	2222	721	24.47		
chr3:37025947	MLH1	nonsynonymous	c.A626G	p.D209G	4189	3242	725	17.1		
chr3:37050487	MLH1	stopgain	c.1899dupT	p.E634*	2225	1589	1217	43.28		
chr3:179204536	PIK3CA	nonsynonymous	c.G1093A	p.E365K	1706	1190	508	29.85		
chr10:87952121	PTEN	frameshift insertion	c.497dupT	p.T167Nfs*13	3258	2607	854	24.64		
chr17:72124335	SOX9	frameshift insertion	c.1479dupC	p.S494Qfs*84	3009	2262	857	27.25		
chr10:13141234	TCF7L2	frameshift insertion	c.175dupC	p.L60Sfs*7	2834	2365	1314	35.39		
chr17:7675140	TP53	nonsynonymous	c.C472T	p.R158C	2243	1395	846	37.72		

CC16056	chr5:112838007	APC	stopgain	c.C2413T	p.R805*	3842	3363	473	12.32		
	chr12:25245350	KRAS	nonsynonymous	c.G35C	p.G12A	7850	5479	2367	30.15	yes	0.43
	chr17:7673776	TP53	nonsynonymous	c.C844T	p.R282W	2675	1866	807	30.17	yes	0.11
CC16057	chr17:7674894	TP53	stopgain	c.C637T	p.R213*	6914	5266	1456	21.14	yes	0
	chr17:7675237	TP53	splicing	c.376-1G>A		2716	2013	703	25.87		
CC16058	chr2:147926138	ACVR2A	nonsynonymous	c.A1000G	p.R334G	828	721	107	12.92		
	chrX:64192583	AMER1	nonsynonymous	c.C704T	p.P235L	250	42	34	44.74		
	chr5:112780895	APC	stopgain	c.C637T	p.R213*	3101	2512	583	18.78		
	chr7:140924640	BRAF	nonsynonymous	c.G64A	p.D22N	3979	1662	2299	58.04		
	chr4:152328232	FBXW7	nonsynonymous	c.G1394A	p.R465H	7171	5373	1796	25.03		
	chr12:25245350	KRAS	nonsynonymous	c.G35C	p.G12A	7807	6214	1591	20.38	yes	0
	chr17:7673775	TP53	nonframeshift insertion	c.448_449insACC	p.D149_R150insH	3013	2195	813	26.89	yes	2.05
CC16060	chr17:7673802	TP53	nonsynonymous	c.G818A	p.R273H	6995	1890	5098	72.85	yes	1.22

<sup>a</sup> Variant allele frequency,

<sup>b</sup> Plasma DNA was evaluated by dPCR,

<sup>c</sup> Variant circulating tumor DNA



## Supplementary Figure S1. Somatic mutation profile of primary CRC tumors from the 52 patients in the current study cohort.

Mutated genes that satisfied the criteria of each set are shown. The top row indicates the patient ID. Genes listed in the custom panel are arranged on the left side of the panel. The detailed mutation profile for Set 1 is available in our previous report (Ref. 35 in the main text). Green boxes indicate the presence of mutations.



continues



Supplementary Figure S2 conitinued



continues

### Supplementary Figure S2 conitinued



continues



Supplementary Figure S2 conitinued

**Supplementary Figure S2. Dynamics of ctDNA in 42 patients with CRC without clinical relapse.** VAF, variant allele frequency.



Supplementary Figure S3. Longitudinal CEA monitoring of patients with CRC during the postoperative period. CEA, carcinoembryonic antigen.



#### Supplementary Figure S4. Comparison of relapse free survival (RFS) rates according to relapse type.

(A) Clinical-RFS rates with CTs every 3-4 months and estimated clinical-RFS with once-a-year CTs. (B) Clinical-RFS and ctDNA-RFS rates. (C) Estimated clinical-RFS with once-a-year CTs and ctDNA-RFS rates. P values were derived using the Kaplan-Meier log-rank test. HR was calculated using the log-rank test. HR, ctDNA, circulating tumor DNA; CT, computed tomography scan; HR, hazard ratio.